Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome:A systematic narrative appraisal of where we are now!
暂无分享,去创建一个
[1] J. Amiral,et al. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes , 2022, Transfusion and Apheresis Science.
[2] Jerard Seghatchian. Spotlight on SARS CoV-2 infection inducing autoimmunity, through the formation of autoantibody to self hemostatic components or to host cells, often leading to severe thrombotic or bleeding events , 2022, Transfusion and Apheresis Science.
[3] A. Heine,et al. Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors , 2022, Frontiers in Immunology.
[4] Xinwei Wu,et al. Variations in oral microbiome and its predictive functions between tumorous and healthy individuals. , 2022, Journal of medical microbiology.
[5] A. Geraldo,et al. The effect of probiotic use on ABO antibody titers , 2022, Immunohematology.
[6] A. Naing,et al. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience , 2022, Journal of hematology.
[7] A. Wolanskyj-Spinner,et al. Immunotherapy-associated Autoimmune Hemolytic Anemia. , 2022, Hematology/oncology clinics of North America.
[8] P. Gilbar,et al. Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab. , 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[9] Huiqin Jiang,et al. The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching , 2022, Journal of Cancer.
[10] J. Brahmer,et al. Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review , 2021, Annals of Hematology.
[11] C. Berking,et al. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis , 2021, Frontiers in Oncology.
[12] G. Otterson,et al. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival , 2021, Cancer Immunology, Immunotherapy.
[13] F. Petrelli,et al. Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review , 2021, Frontiers in Immunology.
[14] Y. Jeon,et al. Blood transfusion had no influence on the 5-year biochemical recurrence after robot-assisted radical prostatectomy: a retrospective study , 2021, BMC Urology.
[15] C. Solinas,et al. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2021, Targeted Oncology.
[16] Y. Lou,et al. Immune‐related hematologic adverse events in the context of immune checkpoint inhibitor therapy , 2021, American journal of hematology.
[17] V. Wong,et al. Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors , 2021, Journal of the advanced practitioner in oncology.
[18] C. Berking,et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. , 2021, European journal of cancer.
[19] M. Thomas,et al. How I treat microangiopathic hemolytic anemia in patients with cancer , 2021, Blood.
[20] A. Zaniboni,et al. Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis , 2021, Surgery Today.
[21] K. Devarajan,et al. 180 The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy , 2020 .
[22] S. Stowell,et al. Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy , 2020, Transfusion.
[23] B. Lash,et al. Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A Case Report and Review of the Literature , 2020, Cureus.
[24] T. Carson,et al. Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review , 2020, Gut Pathogens.
[25] B. Weiner,et al. Intervention strategies for microbial therapeutics in cancer immunotherapy , 2020, Immuno-oncology technology.
[26] M. Matsumoto,et al. Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin , 2020, Internal medicine.
[27] E. Haralambieva,et al. Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect , 2020, BMC Cancer.
[28] S. Zschiedrich,et al. Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma , 2020, CEN Case Reports.
[29] H. Abdel-Razeq,et al. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. , 2019, Critical reviews in oncology/hematology.
[30] A. Raina,et al. Pembrolizumab-induced thrombotic thrombocytopenic purpura , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[31] O. Lambotte,et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? , 2019, European journal of cancer.
[32] M. Davies. Acute and Long-term Adverse Events Associated With Checkpoint Blockade. , 2019, Seminars in oncology nursing.
[33] R. Dronca,et al. Immune Checkpoint Inhibitor Toxicities. , 2019, Mayo Clinic proceedings.
[34] S. Minatoguchi,et al. Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer , 2019, Respiratory medicine case reports.
[35] I. Siddiqi,et al. Bone Marrow Findings of Immune-Mediated Pure Red Cell Aplasia Following Anti-Programmed Cell Death Receptor-1 Therapy: A Report of Two Cases and Review of Literature , 2019, Journal of hematology.
[36] D. Leaf,et al. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors , 2019, American journal of hematology.
[37] N. M. La‐Beck,et al. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines , 2019, Asia-Pacific journal of oncology nursing.
[38] B. Helmink,et al. The microbiome, cancer, and cancer therapy , 2019, Nature Medicine.
[39] K.,et al. Hematologic Complications of Immune Checkpoint Inhibitors , 2019, The oncologist.
[40] R. Munker,et al. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review , 2018, European journal of haematology.
[41] C. Robert,et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. , 2019, The Lancet. Haematology.
[42] T. Dragovich,et al. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors , 2018, Case reports in hematology.
[43] R. Demontis,et al. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach , 2018, Front. Physiol..
[44] S. Konoplev,et al. Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. , 2018, Blood advances.
[45] Y. Wan,et al. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies , 2018, Drug design, development and therapy.
[46] M. Suarez‐Almazor,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] M. Satoh,et al. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. , 2018, Immunotherapy.
[48] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[49] Q. Hill,et al. Autoimmune hemolytic anemia. , 2015, Hematology. American Society of Hematology. Education Program.
[50] A. Gallamini,et al. Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report , 2017, Hematological oncology.
[51] T. Takenouchi,et al. A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma , 2017, Melanoma research.
[52] D. Yuce,et al. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient , 2017, Oncology Research and Treatment.
[53] J. Seghatchian,et al. Transfusion-related immunomodulation and cancer. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[54] J. Seghatchian,et al. Red blood cell transfusion and outcome in cancer. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[55] G. Ragab,et al. The microbiome and transfusion in cancer patients. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[56] P. Coppo,et al. Thrombotic thrombocytopenic purpura. , 2017, Blood.
[57] J. Lutzky,et al. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP) , 2017, Journal of Immunotherapy for Cancer.
[58] J. McQuade,et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy , 2017, Journal of Immunotherapy for Cancer.
[59] U. Khan,et al. Immunotherapy-associated autoimmune hemolytic anemia , 2017, Journal of Immunotherapy for Cancer.
[60] R. Means. Pure red cell aplasia. , 2016, Hematology. American Society of Hematology. Education Program.
[61] Devin Kennedy,et al. Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy , 2016, Case Reports in Oncology.
[62] G. Kristiansen,et al. Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia , 2016, Case Reports in Oncology.
[63] F. Servant,et al. Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing , 2016, Transfusion.
[64] R. Kefford,et al. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. , 2016, Melanoma research.
[65] S. Nair,et al. Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. , 2016, The New England journal of medicine.
[66] J. Seghatchian,et al. Impact of Transfusion on Cancer Growth and Outcome , 2016, Cancer growth and metastasis.
[67] K. Kabashima,et al. Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] J. Wolchok,et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] D. Agrawal,et al. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. , 2015, Translational research : the journal of laboratory and clinical medicine.
[70] R. Das,et al. Anemia in malignancies: Pathogenetic and diagnostic considerations , 2015, Hematology.
[71] P. Ascierto,et al. Serious haematological toxicity during and after ipilimumab treatment: a case series , 2014, Journal of Medical Case Reports.
[72] G. Niklas Norén,et al. vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues , 2013, Drug Safety.
[73] J. George,et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.
[74] T. Gajewski,et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma , 2009, Cancer Immunology, Immunotherapy.
[75] David Mackey,et al. MAMPs and MIMPs: proposed classifications for inducers of innate immunity , 2006, Molecular microbiology.
[76] M. Pescatori,et al. Perioperative blood transfusions for the recurrence of colorectal cancer. , 2004, The Cochrane database of systematic reviews.
[77] S. Wade,et al. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. , 2004, The American journal of medicine.
[78] H. Ludwig,et al. Symptomatology of anemia. , 2001, Seminars in oncology.
[79] G. Demetri. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy , 2001, British Journal of Cancer.
[80] F. Schildberg,et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] M. R. Mickey,et al. Effect of blood transfusions on subsequent kidney transplants. , 1973, Transplantation proceedings.